使用FRED X血流导向支架治疗颅内动脉瘤：中期血管造影及安全性结果
Treatment of Intracranial Aneurysms with the FRED X Flow Diverter Stent: Mid-term Angiographic and Safety Results.
作者信息
Wen David W, Ayre James, Puthuran Mani, Maliakal Paul, Masri Souhyb, Pullicino Richard, Smith Aubrey, Babatola Feyi, Gravino Gilbert, Abdelsalam Nasr, Nejadhamzeeigilani Hamed, Chandran Arun
机构信息
Department of Neuroradiology, The Walton Centre for Neurology and Neurosurgery, Liverpool, UK.
Department of Neuroradiology, Singapore General Hospital, Outram Road, 169608, Singapore, Singapore.
出版信息
Clin Neuroradiol. 2025 Jan 23. doi: 10.1007/s00062-024-01487-z.
PURPOSE
The aim of our study was to assess the mid-term efficacy and safety of the FRED X flow diverting stent (FDS) in the treatment of intracranial aneurysms. The FRED X FDS is relatively new with limited data on its longer-term effectiveness and safety profile.
METHODS
Patients with intracranial aneurysms treated with the FRED X FDS at two UK centres, between March 2021 and July 2022 with at least 18 months follow-up, were retrospectively reviewed. Clinical, procedural and imaging data was analyzed.
RESULTS
Twenty-two patients with 24 aneurysms treated with the FRED X device, and had completed at least 18 months of follow-up, were included in this study. The rate of complete aneurysm occlusion (Raymond-Roy Class I) was 83.3% at a mean follow-up duration of 21.5 months. One case of major adverse event (4.3%) related to a post-procedural stroke which is also the only case of permanent neurological deficit (4.3%) in our cohort. Three cases of minor adverse events (13.0%) and 2 cases of asymptomatic adverse events (8.7%) were also recorded.
CONCLUSION
Use of the FRED X FDS to treat intracranial aneurysms has acceptable safety profile and efficacy in the mid-term.
目的
本研究旨在评估FRED X血流导向支架（FDS）治疗颅内动脉瘤的中期疗效和安全性。FRED X FDS相对较新，关于其长期有效性和安全性的数据有限。
方法
回顾性分析2021年3月至2022年7月期间在英国两个中心接受FRED X FDS治疗且至少随访18个月的颅内动脉瘤患者。分析临床、手术和影像学数据。
结果
本研究纳入了22例使用FRED X装置治疗24个动脉瘤且至少完成18个月随访的患者。平均随访21.5个月时，动脉瘤完全闭塞率（Raymond-Roy I级）为83.3%。1例主要不良事件（4.3%）与术后卒中有关，这也是我们队列中唯一一例永久性神经功能缺损（4.3%）。还记录了3例轻微不良事件（13.0%）和2例无症状不良事件（8.7%）。
结论
使用FRED X FDS治疗颅内动脉瘤在中期具有可接受的安全性和疗效。
Zotero 插件